[go: up one dir, main page]

CA2288017A1 - Methodes relatives a un appauvrissement des eosinophiles et compositions afferentes - Google Patents

Methodes relatives a un appauvrissement des eosinophiles et compositions afferentes Download PDF

Info

Publication number
CA2288017A1
CA2288017A1 CA002288017A CA2288017A CA2288017A1 CA 2288017 A1 CA2288017 A1 CA 2288017A1 CA 002288017 A CA002288017 A CA 002288017A CA 2288017 A CA2288017 A CA 2288017A CA 2288017 A1 CA2288017 A1 CA 2288017A1
Authority
CA
Canada
Prior art keywords
antibody
less
body weight
binding
weight per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002288017A
Other languages
English (en)
Inventor
Christopher J. Grimaldi
Maureen C. Howard
Robert L. Coffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2288017A1 publication Critical patent/CA2288017A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

L'invention a trait à des compositions de fixation ainsi qu'à diverses méthodes d'utilisation de celles-ci. Elle porte, notamment, sur une méthode consistant à apporter une quantité efficace de la composition de fixation, seule ou associée à d'autres composés, à des éosinophiles, ce qui pour effet d'en réduire la concentration chez un sujet. La composition de fixation est, de préférence, un anticorps monoclonal spécifique de CCR3.
CA002288017A 1997-05-07 1998-05-01 Methodes relatives a un appauvrissement des eosinophiles et compositions afferentes Abandoned CA2288017A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85221897A 1997-05-07 1997-05-07
US08/852,218 1997-05-07
PCT/US1998/008974 WO1998050434A1 (fr) 1997-05-07 1998-05-01 Methodes relatives a un appauvrissement des eosinophiles et compositions afferentes

Publications (1)

Publication Number Publication Date
CA2288017A1 true CA2288017A1 (fr) 1998-11-12

Family

ID=25312766

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002288017A Abandoned CA2288017A1 (fr) 1997-05-07 1998-05-01 Methodes relatives a un appauvrissement des eosinophiles et compositions afferentes

Country Status (5)

Country Link
EP (1) EP0981550A1 (fr)
JP (1) JP2001527410A (fr)
AU (1) AU7366398A (fr)
CA (1) CA2288017A1 (fr)
WO (1) WO1998050434A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
AU7097696A (en) * 1995-10-05 1997-04-28 Shionogi & Co., Ltd. Novel human cc chemokine
EP1012190A4 (fr) * 1996-04-26 2004-04-28 Merck & Co Inc Recepteur d'eotaxine eosinophile

Also Published As

Publication number Publication date
AU7366398A (en) 1998-11-27
JP2001527410A (ja) 2001-12-25
EP0981550A1 (fr) 2000-03-01
WO1998050434A1 (fr) 1998-11-12

Similar Documents

Publication Publication Date Title
US7138117B1 (en) Anti-CCR4 antibodies and methods of use therefor
AU2003213475B2 (en) Anti-CCR2 antibodies and methods of use therefor
US7232567B2 (en) Anti-CCR1 antibodies and methods of use thereof
US20090175877A1 (en) Methods of inhibiting metastasis
US20120141411A1 (en) Uses of IL-174 Antagonists for Inhibiting A Th2 Immune Response
CA2389979C (fr) Procedes d'inhibition de metastases
EP1030865A2 (fr) APPAUVRISSEMENT DE LA CELLULE Th2, COMPOSITIONS ET METHODES EN RAPPORT
US6207155B1 (en) Method of eosinophil depletion with antibody to CCR 3 receptor
CA2288017A1 (fr) Methodes relatives a un appauvrissement des eosinophiles et compositions afferentes
AU2887399A (en) Anti-ccr1 antibodies and methods of use therefor
US6416954B1 (en) Modulating Th2 cell levels via vMIP-I/CCR8 interaction
MXPA99010259A (en) Methods for eosinophil depletion and compositions therefor
AU2004201168A1 (en) Anti-CCR4 antibodies and methods of use therefor
MXPA00004667A (en) Th2 CELL DEPLETION;COMPOSITIONS;METHODS
MXPA01007199A (en) Anti-ccr4 antibodies and methods of use therefor

Legal Events

Date Code Title Description
FZDE Dead